NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Globenewswire·2025-11-28 14:15
TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the third quarter ended September 30, 2025 (“Q3 2025”) and provided a corporate update on recent achievements and upcoming milestones. The Company’s unaudited condensed interim consolidated financ ...